Drug Channels

NOVEMBER 14, 2023

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2024 This event will be broadcast live on Friday, December 15, 2023 12:00 p.m. The webinar will be broadcast from the Drug Channels studio in beautiful downtown Philadelphia. (Or,

Drug Pricing 98

Drug Pricing Biosimilars 98

Drug Channels

NOVEMBER 9, 2022

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new live video webinar: Drug Channels Outlook 2023. The webinar will be broadcast from the Drug Channels studio in beautiful downtown Philadelphia. The webinar will last 90 minutes to accommodate audience questions.

Specialty Pharmacies 98

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 98

Drug Channels

SEPTEMBER 7, 2022

As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. In many therapeutic areas, biosimilars’ market share is approaching 80%. will face multiple biosimilar competitors. The video is excerpted from last month’s Specialty Drugs Update: Trends, Controversies, and Outlook video webinar.

Biosimilars 98

Biosimilars 98

Drug Channels

SEPTEMBER 8, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for his latest video webinar: Drug Channels Update: Buy-and-Bill Market Trends. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. The webinar will be 90 minutes to accommodate audience questions.

Drug Pricing 97

Drug Pricing Biosimilars Hospitals 97

Drug Channels

MARCH 5, 2024

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s latest live video webinar: Drug Channel Implications of the Inflation Reduction Act This event will be broadcast live on Friday, April 5, 2024, from 12:00 p.m. This event is part of The Drug Channels 2024 Video Webinar Series.

Drug Pricing 98

Drug Pricing Biosimilars 98

Safe Biologics

AUGUST 27, 2024

87% of respondents agreed that they are more comfortable switching a patient from an originator biologic to a biosimilar if that medicine has been specifically evaluated for the impact of switching on safety and efficacy. Only 11% believe all biosimilars should be deemed interchangeable. All prescribe biologics. policy here.

Biosimilars 100

Biosimilars 100

Drug Channels

MARCH 26, 2025

Coming soon: PBM Industry Update: Trends, Challenges, and Whats Ahead.Our first webinar of the year will tackle the most controversial drug channel participants. Join my more than 61,000 LinkedIn followers for daily links to neat stuff along with thoughtful and provocative commentary from the DCI community. Join Adam J. Fein, Ph.D.,

Biosimilars 52

Biosimilars 52

Drug Channels

MARCH 28, 2023

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. Below, I highlight four takeaways from this year’s lists, including a look at biosimilar insulin and the forthcoming biosimilar competition for Humira.

Biosimilars 98

Biosimilars 98

Drug Channels

DECEMBER 12, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2023. During Friday’s webinar, I’ll be sharing my updated thoughts about the IRA’s impact on manufacturers, Part D plans, and patient behavior. Click here to see the original post and comments from September 2022.

Biosimilars 98

Biosimilars Hospitals 98

Big Molecule Watch

AUGUST 24, 2023

In continuation of Goodwin’s previous webinar series concerning biosimilars, Big Molecule Watch is launching the 2023-2024 webinar series , which will dive deep into some of the key topics pertaining to this burgeoning industry and corresponding area of law.

Biosimilars 40

Biosimilars Labelling 40

Drug Channels

NOVEMBER 15, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new live video webinar: Drug Channels Outlook 2022. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. The Outlook 2022 marks our third annual outlook webinar. Broadcast live on December 17, 2021.

Specialty Pharmacies 72

Specialty Pharmacies Drug Pricing Biosimilars 72

Big Molecule Watch

NOVEMBER 7, 2023

This webinar will explore topics including: Evolving trends of biologic patent challenges at the PTAB; Strategic considerations for biosimilar manufacturers; and Lessons learned from recent filings. Click here to register for the webinar.

Biosimilars 69

Biosimilars 69

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 130

Biosimilars Drug Pricing Compounding Drug Development 130

Safe Biologics

JULY 20, 2023

REGISTER NOW: July 26th ASBM/GaBI Webinar on IRA Medicare Price Negotiation On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). REGISTER HERE.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Safe Biologics

JULY 20, 2023

REGISTER NOW: July 26th ASBM/GaBI Webinar on IRA Medicare Price Negotiation On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). REGISTER HERE.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Safe Biologics

SEPTEMBER 12, 2023

ASBM & GaBI Webinar on Medicare Price Negotiation Examines Impact on Innovation, Patient Access On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a webinar entitled MEDICARE DRUG PRICE NEGOTIATIONS: Impact on Healthcare Development and Patient Access to Medicines.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Safe Biologics

DECEMBER 3, 2023

ASBM and GaBI Webinar Examines Policy Challenges to Interchangeable Biosimilars On November 30, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted I nterchangeable Designation for Biosimilars- Ensuring Continuity of Patient Care: Upholding Interchangeability Status for Biosimilars.

Biosimilars 130

Biosimilars Labelling Drug Pricing Packaging 130

Drug Channels

JULY 20, 2022

In this issue: CVS disassociates itself from its chain pharmacy association Payers are paying attention to ICER Benefits of the biosimilar boom A fantastic takedown of health insurance deductibles Plus, I join the Advisory Board of Alto Pharmacy. Cut through the steamy summer haze with our refreshing selection of articles and insights.

Biosimilars 98

Biosimilars 98

Drug Channels

DECEMBER 11, 2023

This week, I’m rerunning some popular posts while I prepare for Friday’s Drug Channels Outlook 2024 live video webinar. CVS Health has finally revealed its strategy for biosimilars of AbbVie’s Humira. Click here to see the original post from September 2023.

Biosimilars 75

Biosimilars Labelling 75

Drug Channels

MARCH 30, 2023

This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. So far, it appears that PBMs are neither preferring Amgen's Humira biosimilar nor embracing the low-list/low-rebate version.

Biosimilars 75

Biosimilars 75

Drug Channels

APRIL 19, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: PBM Industry Update: Trends, Controversies, and Outlook. An ironic postcript: Less than two months after my article was published, Cigna CEO David Cordani bragged about the cost savings from "aggressive adoption" of biosimilars.

Biosimilars 75

Biosimilars Drug Pricing 75

Safe Biologics

NOVEMBER 12, 2023

View the full webinar here or watch individual segments linked below. 6 “The Biosimilar Red Tape Elimination Act”, which would prevent the HHS Secretary from requiring switching studies in order for a biosimilar to be deemed “interchangeable” Under U.S. ASBM surveys of U.S.

Biosimilars 130

Biosimilars Drug Pricing Packaging Labelling 130

Safe Biologics

OCTOBER 10, 2023

Clip 4: Panel Discussion – View clip. Full Webinar – View the full webinar here. FDA Approves First U.S. director of the Office of Therapeutic Biologics and Biosimilars in the FDA’s Center for Drug Evaluation and Research. Tyruko (natalizumab-sztn) is the 42nd biosimilar approved by the U.S.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 100

Biosimilars Drug Pricing Compounding Drug Development 100

FDA Law Blog: Biosimilars

JUNE 10, 2024

Director Larry Houck will participate as a panelist focusing on this timely topic in the Food and Drug Law Institute’s (“FDLI’s”) “High Time for a Change: Implications of DEA’s Proposed Marijuana Rescheduling” webinar June 12, 2024, 2:00-3:30 pm ET.

Controlled Substances 59

Controlled Substances 59

Putting Patients First Blog

MAY 26, 2023

Biosimilars briefing Event Time: 2:00 - 3:00 p.m. ET Event Location: Virtual The National Health Council invites you to join us for a webinar on the latest developments with biosimilars on Monday, June 12 at 2 p.m. This briefing will focus on the value biosimilars hold for patient communities and our health care system.

Biosimilars 52

Biosimilars Communication 52

Big Molecule Watch

OCTOBER 5, 2023

The world of biosimilar litigation is back in full swing with several BPCIA lawsuits currently pending. Click here to register for the webinar. The post Patent Dance Disclosures and Beyond: Recent Biosimilars Litigation at the District Court appeared first on Big Molecule Watch.

Biosimilars 53

Biosimilars 53

Drug Channels

FEBRUARY 4, 2025

Outline the market access implications for provider-administered biosimilars in the buy-and-bill market. This video was excerpted from my recent Drug Channels Outlook 2025 webinar. Click here if you cant see the video below. 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Biosimilars 52

Biosimilars 52

Drug Channels

MARCH 31, 2022

Along with sunshine and fine weather, this vernal equinox has ushered in a crop of new and noteworthy stories: Health inequities in utilization management Insurers compute big white bagging savings The biosimilar boom accelerates The patient upside of manufacturers’ copay support Whoa. CVS Health takes the red pill.

Biosimilars 75

Biosimilars 75

Safe Biologics

FEBRUARY 1, 2024

The CHMP recognizes that there may be the potential to waive certain clinical data requirements even for complex biosimilars such as mAbs based on solid evidence of quality comparability.

Biosimilars 130

Biosimilars Documentation Drug Pricing 130

Safe Biologics

DECEMBER 8, 2022

ASBM Advisory Board Chair Philip Schneider, MS, FASHP, FFIP gave a presentation entitled “Key Factors for Improving Sustainability in Biosimilar Markets”. The presentation reflected the findings from a recent webinar ASBM held on this subject with GaBI Journal. Read the GaBI Journal report of the webinar here.

Biosimilars 100

Biosimilars Communication Drug Development 100

Safe Biologics

JANUARY 12, 2024

The automatic substitution of biosimilars is a controversial practice, banned in many countries including nearly all of Western Europe. Oregon state law currently only permits biosimilars that the FDA has approved as interchangeable to be automatically substituted.

Biosimilars 130

Biosimilars Drug Pricing 130

Safe Biologics

DECEMBER 6, 2023

prescribers have high confidence in the safety and efficacy of biosimilars, a majority (58%) oppose third-party switching of a patient’s biologic medicine for non-medical (e.g. state law, only biosimilars which are interchangeable may be substituted by a pharmacist without contacting the prescriber. and worldwide.”

Biosimilars 130

Biosimilars Packaging Labelling Drug Development 130

Drug Channels

MAY 30, 2023

Speaking of PBMs, be sure to join me for my new live video webinar, PBMs and the Battle Over Patient Support Funds: Accumulators, Maximizers, and Alternative Funding , on June 23, 2023, from 12:00 p.m. I recommend that you follow me on LinkedIn, because the quality of comments is much higher than they are on Twitter.) to 1:30 p.m.

Hospitals 75

Hospitals Biosimilars 75

Drug Channels

DECEMBER 17, 2020

This week, I’m rerunning some popular posts while I prepare for this Friday’s video webinar: Drug Channels Outlook 2021. Conveniently for HHS, ASPE's analysis stopped before the biosimilar boom began. The biosimilar market is finally beginning to fulfill its promise. Drug pricing perceptions always seem to lag reality.

Biosimilars 52

Biosimilars Drug Pricing 52

FDA Law Blog: Biosimilars

SEPTEMBER 22, 2024

The webinar largely consisted of summarizing the general requirements under Parts 803, 806 and 820.198, which we do not reproduce here ( but see another of our prior blog posts discussing these requirements and their applicable to LDTs in greater detail; you can also find FDA’s slides from the webinar here ). By Steven J.

Labelling 64

Labelling Communication 64

FDA Law Blog: Biosimilars

MARCH 12, 2023

Please see detailed information in the attached flyer , including a link to register for our free webinar. John will present on considerations and his learned perspective for the future of teleprescribing. We hope you join us!

Controlled Substances 98

Controlled Substances 98